Dehydroepiandrosterone-mediated stimulation of sigma-1 receptor activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding

Cardiovascular Therapeutics

Volumn 29, Issue 4, 2011, Pages 219-230

  Bhuiyan, Md Shenuarin ^a   Tagashira, Hideaki ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Dehydroepiandrosterone (DHEA); Endothelial nitric oxide synthase (eNOS); Myocardial hypertrophy; Protein kinase B (Akt); Sigma 1 receptor (Sig 1R)

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PRASTERONE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; SIGMA 1 OPIATE RECEPTOR;

ABDOMINAL AORTIC BANDING; AORTA STENOSIS; AORTA SURGERY; ARTICLE; DISEASE COURSE; FEMALE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; NONHUMAN; OVARIECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; DEHYDROEPIANDROSTERONE; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SIGNAL TRANSDUCTION;

EID: 79960257318     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00196.x     Document Type: Article

References (78)

1. Shono N, Kumaga S, Higaki Y, Nishizumi M, Sasaki H. The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. J Atherosclerosis Thrombosis 1996;3:45-51.
2. Okamoto K. Relationship between dehydroepiandrosterone sulfate and serum lipid levels in Japanese men. J Epidemiol 1996;6:63-67.
3. Okamoto K. Distribution of dehydroepiandrosterone sulfate and relationships between its level and serum lipid levels in a rural Japanese population. J Epidemiol 1998;8:285-291.
4. Nagata C, Takatsuka N, Kabuto M, Shimizu H. Association of dehydroepiandrosterone sulfate with serum HDL-cholesterol concentrations in post-menopausal Japanese women. Maturitas 1998;31:21-27.
5. Abbasi A, Duthie EH, Sheldahl L, et al. Association of dehydroepiandrosterone sulfate, body composition, and physical fitness in independent community-dwelling older men and women. J Am Geriatr Soc 1998;46:263-273.
6. Thompson DL, Snead DB, Seip RL, et al. Serum lipid levels and steroidal hormones in women runners with irregular menses. Can J Appl Physiol 1997;22:66-77.
7. Young DG, Skibinski G, Mason JI, James K. The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta 1 (TGF-beta1) levels in normal healthy blood donors. Clin Exp Immunol 1999;117:476-481.
8. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: A review. Atherosclerosis 1996;125:1-13.
9. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001;86:4171-4177.
10. Feldman HA, Johannes CB, Araujo AB, et al. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: Prospective results from the Massachusetts male aging study. Am J Epidemiol 2001;153:79-89.
11. Herrington DM, Gordon GB, Achuff SC, et al. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 1990;16:862-870.
12. Herrington DM, Nanjee N, Achuff SC, et al. Dehydroepiandrosterone and cardiac allograft vasculopathy. J Heart Lung Transplant 1996;15:88-93.
13. Kiechl S, Willeit J, Bonora E, Schwarz S, Xu Q. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck study). Arterioscler Thromb Vasc Biol 2000;20:1094-1100.
14. Bernini GP, Moretti A, Sgro M, et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001;8:43-50.
15. Bernini GP, Sgro' M, Moretti A, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 1999;84:2008-2012.
16. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: The study of women's health across the nation. J Clin Endocrinol Metab 2005;90:4836-4845.
17. Barna I, Feher T, de Chatel R. Relationship between blood pressure variability and serum dehydroepiandrosterone sulfate levels. Am J Hypertens 1998;11:532-538.
18. 4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care 1996;19:1045-1050.
19. Akishita M, Hashimoto M, Ohike Y, et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res 2008;31:69-74.
20. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann NY Acad Sci 1995;774:271-280.
21. Mortola JF, Yen SCC. The effects of oral dehydroepiandrosterone on endocrine-metabolic in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704.
22. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145:457-461.
23. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003;88:3190-3195.
24. Szathmári M, Treszl A, Vásárhelyi B. Left ventricular mass index and ventricular septum thickness are associated with serum dehydroepiandrosterone-sulphate levels in hypertensive women. Clin Endocrinol (Oxf) 2003;59:110-114.
25. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
26. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 1988;82:712-720.
27. Lea-Currie YR, Wu SM, McIntosh MK. Effects of acute administration of dehydroepiandrosterone-sulfate on adipose tissue mass and cellularity in male rats. Int J Obes Relat Metab Disord 1997;21:147-154.
28. Regelson W, Kalimi M. Dehydroepiandrosterone (DHEA)-the multifunctional steroid. II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action? Ann NY Acad Sci 1994;719:564-575.
29. Aragno M, Parola S, Brignardello E, et al. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes 2000;49:1924-1931.
30. Ayhan S, Tugay C, Norton S, Araneo B, Siemionow M. Dehydroepiandrosterone protects the microcirculation of muscle flaps from ischemia-reperfusion injury by reducing the expression of adhesion molecules. Plast Reconstr Surg 2003;111:2286-2294.
31. Barbagallo M, Shan N, Pang PK, Resnick LM. Effects of dehydroepiandrosterone sulfate on cellular calcium responsiveness and vascular contractility. Hypertension 1995;26:1065-1069.
32. Farrukh IS, Peng W, Orlinska U, Hoidal JR. Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: A Ca(2+)-activated K(+)-channel opener. Am J Physiol 1998;274:L186-L195.
33. Yoshimata T, Yoneyama A, Jin-no Y, Tamai N, Kamiya Y. Effects of dehydroepiandrosterone on mitogen-activated protein kinase in human aortic smooth muscle cells. Life Sci 1999;65:431-440.
34. Yoneyama A, Kamiya Y, Kawaguchi M, Fujinami T. Effects of dehydroepiandrosterone on proliferation of human aortic smooth muscle cells. Life Sci 1997;60:833-838.
35. Mohan PF, Benghuzzi H. Effect of dehydroepiandrosterone on endothelial cell proliferation. Biomed Sci Instrum 1997;33:550-555.
36. Khalil A, Lehoux JG, Wagner RJ, et al. Dehydroepiandrosterone protects low density lipoproteins against peroxidation by free radicals produced by gamma-radiolysis of ethanol-water mixtures. Atherosclerosis 1998;136:99-107.
37. Mohan PF, Jacobson MS. Inhibition of macrophage superoxide generation by dehydroepiandrosterone. Am J Med Sci 1993;306:10-15.
38. Taniguchi S, Yanase T, Kobayashi K, Takayanagi R, Nawata H. Dehydroepiandrosterone markedly inhibits the accumulation of cholesteryl ester in mouse macrophage J774-1 cells. Atherosclerosis 1996;126:143-154.
39. Williams MR, Ling S, Dawood T, et al. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002;87:176-181.
40. Hayashi T, Esaki T, Muto E, et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: The possible role of nitric oxide. Arterioscler Thromb Vasc Biol 2000;20:782-792.
41. Simoncini T, Mannella P, Fornari L, et al. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinol 2003;144:3449-3455.
42. Leblanc M, Labrie C, Belanger A, Candas B, Labrie F. Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J Ster Biochem Mol Biol 2002;81:159-164.
43. Labrie F, Belanger L, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology. J Clin Endocrinol Metab 1997;82:2403-2409.
44. Ueda H, Yoshida A, Tokuyama S, et al. Neurosteroids stimulate G protein-coupled sigma receptors in mouse brain synaptic membrane. Neurosci Res 2001;41:33-40.
45. Maurice T, Gregoire C, Espallergues J. Neuro(active)steroids actions at the neuromodulatory sigmal (sigma 1) receptor: Biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav 2006;84:581-597.
46. Cheng ZX, Lan DM, Wu PY, et al. Neurosteroid dehydroepiandrosterone sulphate inhibits persistent sodium currents in rat medial prefrontal cortex via activation of sigma-1 receptors. Exp Neurol 2008;210:128-136.
47. Morin-Surun MP, Colin T, avit-Saubie M, Baulieu EE, Monnet FP. Intracellular sigma 1 receptor modulates phospholipase C and protein kinase C activities in brain stem. Proc Natl Acad Sci USA 1999;96:8196-8199.
48. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab 2007;293:E1606-E1614.
49. Bhuiyan MS, Shioda N, Shibuya M, Iwabuchi Y, Fukunaga K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 2009;53:57-63.
50. Yamada J, Sakuma M, Suga T. Assay of fatty acid ω-hydroxylation using high performance liquid chromatography with fluorescence labeling reagent, 3-bromomethyl-7-methoxy-1, 4-benzoxazin-2-one (BrMB). Analytical Biochem 1991;199:132-136.
51. Dobonneuil EH, Quillard J, Baulieu EE. Hypoxia and dehydroepiandrosterone in old age: A mouse survival study. Respiratory Res 2006;7:144.
52. Bonnet S, Dumas-de-La-Roque E, Bégueret H, et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 2003;100:9488-9493.
53. Baulieu EE. Dehydroepiandrosterone (DHEA): A fountain of youth? J Clin Endocrinol Metab 1996;88:3147-3151.
54. Longcope C. Metabolism of DHEA. Ann NY Acad Sci 1995;774:143-148.
55. Okuyama S, Nakazato A. NE-100: A novel sigma receptor antagonist. CNS Drug Reviews 1996;2:226-237.
56. Hiyoshi H, Yayama K, Takano M, Okamoto H. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 2005;45:967-973.
57. Jackson DE. The unfolding tale of PECAM-1. FEBS Lett 2003;540:7-14.
58. Geol R, Boylan B, Gruman L, et al. The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;293:G1205-G1214.
59. Graesser D, Solowiej A, Bruckner M, et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-defecient mice. J Clin Invest 2002;109:383-392.
60. Mass M, Stapleton M, Bergom C, et al. Endothelial cell PECAM-1 confers protection against endotoxic shock. Am J Physiol Heart Circ Physiol 2005;288:H159-H164.
61. Carrithers M, Tandon S, Canosa S, et al. Enhanced susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice. Am J Pathol 2005;166:185-196.
62. Zeng G, Nystrom Fh, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-1545.
63. Fulton D, Gratton J-P, Sessa WC. Post-translational control of endothelial nitric oxide synthase: Why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-824.
64. i protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinol 2007;148:3068-3076.
65. Williams MR, Dawood T, Ling S, et al. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 2004;89:4708-4715.
66. Formoso G, Chen H, Kim JA, et al. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol 2006;20:1153-1163.
67. Partovian C, Zhuang Z, Moodie K, et al. PKC activates eNOS and increases arterial blood flow in vivo. Circ Res 2005;97:482-487.
68. Charalampopoulos I, Tsatsanis C, Dermitzaki E, et al. Dehydroepiandrosterone and allopregnanolone protects sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acd Sci 2004;101:8209-8214.
69. Hutchison SJ, Browne AE, Ko E, et al. Dehydroepiandrosterone sulfate induces acute vasodilation of procine coronary arteries in vitro and in vivo. J Cardiovasc Pharmacol 2005;46:325-332.
70. i2, 3. J Biol Chem 2002;277:21379-21388.
71. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: Evidence for a cell surface receptor. Steroids 2004;69:279-289.
72. Wang L, Duncan G. Silencing of sigma-1 receptor induces cell death in human lens cells. Exp Cell Res 2006;312:1439-1446.
73. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004;64:4875-4886.
74. Zapata E, Ventura JL, De la Cruz K, et al. Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent. FEBS J 2005;272:1343-1353.
75. Bhuiyan MS, Fukunaga K. Stimulation of sigma-1 receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats. Expert Opin Ther Targets 2009;13:1253-1265.
76. Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003;21:346-355.
77. Genazzani AD, Stomati M, Bernardi F, et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal woman modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003;80:1495-1501.
78. Swierczynski J, Mayer D. Dehydroepiandrosterone induced lipid peroxidation in rat liver mitochondria. J Steroid Biochem Mol Biol 1996;58:599-603.